Skip to main content

Table 6 Cost estimates used in the decision analytic models. Costs in US dollars.

From: Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis

Costs

Model with all patients

Model in patients with APACHE II score >= 25

Source

Drug costs * (drotrecogin alfa)

$9,700

$9,700

MUHC (Pharmacy department)

Bleeding episode costs

$12,090

$12,090

Manns et al [40]

Hospitalization costs (severe sepsis episode)

$47,960

$51,095

Manns et al. [40]

1-year costs (after hospital discharge)**

$20,641

$29,879

Manns et al. [40]

Year 2 costs**

$6,641

$8,083

Manns et al. [40]

Year 3 costs**

$6,290

$5,762

Manns et al. [40]

  1. * Drug costs refer to acquisition costs of drotrecogin alfa and were therefore used only in this group. Other costs were assumed to be identical in both groups.
  2. Costs from the article by Manns et al. [40] were converted to Canadian dollars according to the exchange rate used in the article (US$1 = CDN$1.47) and adjusted for inflation according to Bank of Canada rates.
  3. ** Costs with 3% discounting
  4. This included direct health care costs for hospitalizations, emergency visits, day surgeries, and physicians' costs [40].
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us